Business

Zydus Lifesciences Set to Acquire Majority Stake in French MedTech Firm Amplitude Surgical

Under the terms of the deal, Zydus will initially invest Rs 2,446 crore to acquire 85.6% of Amplitude Surgical’s share capital at a price of Rs 6.25 per share. Following the completion of this controlling stake acquisition, the company is set to launch a mandatory cash tender offer for the remaining shares at the same price. The total valuation for a full 100% takeover stands at around Rs 2,856 crore (€300 million).

• By Newsdesk
• New Delhi
• Mar 13, 2025

Business

In a strategic move to expand its footprint in the global medical technology sector, Ahmedabad-based Zydus Lifesciences has entered exclusive negotiations to acquire a controlling stake in France’s Amplitude Surgical for approximately Rs 2,446 crore (€257 million). This acquisition marks a significant milestone for Zydus as it ventures into the medtech space, diversifying its business beyond pharmaceuticals.

Under the terms of the deal, Zydus will initially invest Rs 2,446 crore to acquire 85.6% of Amplitude Surgical’s share capital at a price of Rs 6.25 per share. Following the completion of this controlling stake acquisition, the company is set to launch a mandatory cash tender offer for the remaining shares at the same price. The total valuation for a full 100% takeover stands at around Rs 2,856 crore (€300 million).

Commenting on the development, Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the strategic importance of this acquisition. “This marks our foray into the global medtech sector, a natural extension of our expertise in medical technologies. Our commitment to quality, continuous R&D investments, and manufacturing excellence will drive our success in this highly specialized field,” Patel stated in a press briefing.

The negotiations involve PAI Partners, Amplitude Surgical’s management, and two minority shareholders. Zydus plans to fund the transaction through a combination of internal accruals and a modest amount of debt. As of December 31, 2024, the company reported a net cash reserve of Rs 3,092 crore. Following the announcement, Zydus Lifesciences' shares closed 0.75% higher at Rs 899.90 on the Bombay Stock Exchange (BSE) on Tuesday.

Amplitude Surgical, a leading European medical technology firm, specializes in high-quality lower-limb orthopedic solutions. The company is known for its cutting-edge innovations in knee and hip prostheses, which aid patients, surgeons, and healthcare facilities worldwide. In the fiscal year ending June 30, 2024, Amplitude Surgical recorded revenues of €106 million and an EBITDA of €27.1 million, showcasing strong financial performance.

Looking ahead, Zydus aims to capitalize on this acquisition to strengthen its position in the global medical devices market. Patel outlined the company’s long-term vision, stating, “Over the next five to seven years, we see immense potential to build a substantial medical devices business, particularly in arthroplasty, cardiology, and nephrology. Our growth strategy includes both organic expansion and strategic acquisitions.”

He further highlighted that this move aligns with Zydus’ broader vision of enhancing patient-centric healthcare solutions beyond pharmaceuticals. “This acquisition is a step towards a more holistic approach to healthcare, integrating advanced technology with patient care,” Patel added.

The deal underscores Zydus Lifesciences' ambition to diversify into high-growth segments of the healthcare industry, reinforcing its commitment to innovation and global expansion.